

David Groheux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6961026/publications.pdf>

Version: 2024-02-01

63
papers

3,119
citations

186265

28
h-index

155660

55
g-index

71
all docs

71
docs citations

71
times ranked

3030
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | ¹⁸ F-FDG PET Uptake Characterization Through Texture Analysis: Investigating the Complementary Nature of Heterogeneity and Functional Tumor Volume in a Multi-Cancer Site Patient Cohort. <i>Journal of Nuclear Medicine</i> , 2015, 56, 38-44. | 5.0 | 374 |
| 2 | Correlation of high ¹⁸ F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 426-435. | 6.4 | 337 |
| 3 | Performance of FDG PET/CT in the Clinical Management of Breast Cancer. <i>Radiology</i> , 2013, 266, 388-405. | 7.3 | 224 |
| 4 | ¹⁸ F-FDG PET/CT for Staging and Restaging of Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 17S-26S. | 5.0 | 135 |
| 5 | Prognostic Impact of ¹⁸ F-FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1879-1887. | 6.3 | 133 |
| 6 | Effect of ¹⁸ F-FDG PET/CT Imaging in Patients With Clinical Stage II and III Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 695-704. | 0.8 | 114 |
| 7 | ¹⁸ F-FDG PET/CT in Staging Patients with Locally Advanced or Inflammatory Breast Cancer: Comparison to Conventional Staging. <i>Journal of Nuclear Medicine</i> , 2013, 54, 5-11. | 5.0 | 114 |
| 8 | FDG PET-CT for solitary pulmonary nodule and lung cancer: Literature review. <i>Diagnostic and Interventional Imaging</i> , 2016, 97, 1003-1017. | 3.2 | 103 |
| 9 | The Yield of ¹⁸ F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1526-1534. | 5.0 | 99 |
| 10 | Triple-Negative Breast Cancer: Early Assessment with ¹⁸ F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse. <i>Journal of Nuclear Medicine</i> , 2012, 53, 249-254. | 5.0 | 91 |
| 11 | Good clinical practice recommendations for the use of PET/CT in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 28-50. | 6.4 | 85 |
| 12 | The Sentinel Node Procedure in Breast Cancer: Nuclear Medicine as the Starting Point. <i>Journal of Nuclear Medicine</i> , 2011, 52, 405-414. | 5.0 | 82 |
| 13 | Comparison Between ¹⁸ F-FDG PET Image-Derived Indices for Early Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 341-349. | 5.0 | 74 |
| 14 | Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype. <i>Radiology</i> , 2015, 277, 358-371. | 7.3 | 72 |
| 15 | ¹⁸ F-FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis. <i>Breast Cancer Research</i> , 2017, 19, 3. | 5.0 | 67 |
| 16 | Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with ¹⁸ F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1145-1154. | 6.4 | 65 |
| 17 | Early monitoring of response to neoadjuvant chemotherapy in breast cancer with ¹⁸ F-FDG PET/CT: defining a clinical aim. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 419-425. | 6.4 | 64 |
| 18 | Do clinical, histological or immunohistochemical primary tumour characteristics translate into different ¹⁸ F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1682-1691. | 6.4 | 63 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment. <i>British Journal of Cancer</i> , 2013, 109, 1157-1164. | 6.4 | 59 |
| 20 | 18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 983-993. | 6.4 | 58 |
| 21 | Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. <i>European Journal of Cancer</i> , 2014, 50, 1864-1871. | 2.8 | 53 |
| 22 | Baseline Tumor ¹⁸ F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2 ⁻ Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 824-831. | 5.0 | 48 |
| 23 | Estrogen receptor ⁺ /human epidermal growth factor receptor 2 ⁻ negative breast tumors. <i>Cancer</i> , 2013, 119, 1960-1968. | 4.1 | 47 |
| 24 | Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 377-385. | 6.4 | 46 |
| 25 | ¹⁸ F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen. <i>Journal of Nuclear Medicine</i> , 2016, 57, 536-543. | 5.0 | 40 |
| 26 | Lymphoscintigraphy Can Select Breast Cancer Patients for Internal Mammary Chain Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1081-1088. | 0.8 | 37 |
| 27 | Breast cancer: initial workup and staging with FDG PET/CT. <i>Clinical and Translational Imaging</i> , 2021, 9, 221-231. | 2.1 | 34 |
| 28 | Variation of Liver SUV on 18FDG-PET/CT Studies in Women With Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 422-425. | 1.3 | 30 |
| 29 | Role of SPECT/CT in Sentinel Lymph Node Detection in Patients With Breast Cancer. <i>Clinical Nuclear Medicine</i> , 2014, 39, 431-436. | 1.3 | 30 |
| 30 | Hypoxia Imaging of Uterine Cervix Carcinoma With 18F-FETNIM PET/CT. <i>Clinical Nuclear Medicine</i> , 2012, 37, 1065-1068. | 1.3 | 27 |
| 31 | Should FDG PET/CT be used for the initial staging of breast cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1539-1542. | 6.4 | 22 |
| 32 | 18F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer. <i>European Journal of Radiology</i> , 2014, 83, 1925-1933. | 2.6 | 22 |
| 33 | FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 508-519. | 4.6 | 22 |
| 34 | Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1279-1288. | 6.4 | 21 |
| 35 | Role of Fludeoxyglucose in Breast Cancer. <i>PET Clinics</i> , 2018, 13, 395-414. | 3.0 | 21 |
| 36 | The evolving role of PET/CT in breast cancer. <i>Nuclear Medicine Communications</i> , 2010, 31, 271-273. | 1.1 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | 18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients. <i>Oncotarget</i> , 2018, 9, 16343-16353. | 1.8 | 15 |
| 38 | Predicting pathological complete response in breast cancer early. <i>Lancet Oncology</i> , The, 2014, 15, 1415-1416. | 10.7 | 14 |
| 39 | FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1417-1419. | 6.4 | 14 |
| 40 | Pathological complete response in breast cancer. <i>Lancet</i> , The, 2015, 385, 114. | 13.7 | 8 |
| 41 | Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsyâ€”FDG-PET/CT. <i>PET Clinics</i> , 2011, 6, 9-25. | 3.0 | 6 |
| 42 | Breast Cancer Patient With an Uncommon Lymphatic Drainage Evidenced by SPECT/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e176-e179. | 1.3 | 6 |
| 43 | Breast Cancer Staging: To Which Women Should ¹⁸ F-FDG PET/CT Be Offered?. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1293.1-1293. | 5.0 | 6 |
| 44 | Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis. <i>Anticancer Research</i> , 2015, 35, 1729-34. | 1.1 | 6 |
| 45 | Cryptorchidism as a potential source of misinterpretation in 18FDG-PET imaging in restaging lymphoma patients. <i>Biomedicine and Pharmacotherapy</i> , 2013, 67, 533-538. | 5.6 | 5 |
| 46 | ¹⁸ F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 683.1-683. | 5.0 | 5 |
| 47 | Effect of variation in relaxation parameter value on LOR-RAMLA reconstruction of 18F-FDG PET studies. <i>Nuclear Medicine Communications</i> , 2009, 30, 926-933. | 1.1 | 4 |
| 48 | Whole-body 18FDGâ€”PET/CT or whole-body gadolinium-enhanced MRI for distant staging?. <i>Annals of Oncology</i> , 2013, 24, 9-13. | 1.2 | 4 |
| 49 | FDG PET/CT in Ovarian Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 54-56. | 1.3 | 3 |
| 50 | Breast infiltration by relapsed acute lymphoblastic leukaemia on FDG PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 811-812. | 6.4 | 3 |
| 51 | Internal Mammary Node Irradiation in Breast Cancer: The Issue of Patient Selection. <i>Journal of Clinical Oncology</i> , 2016, 34, 2673-2674. | 1.6 | 3 |
| 52 | Now Is the Time to Use ¹⁸ F-FDG PET/CT to Optimize Neoadjuvant Treatment in Triple-Negative Breast Cancer!. <i>Journal of Nuclear Medicine</i> , 2018, 59, 863-864. | 5.0 | 3 |
| 53 | Is 18FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1571-1573. | 6.4 | 2 |
| 54 | Letter to the Editor: PET/CT in Locally Advanced Breast Cancer: Time for a Guideline Change?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, xxx. | 4.9 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy. <i>Cancers</i> , 2022, 14, 1331. | 3.7 | 2 |
| 56 | Patient Selection for Internal Mammary Node Irradiation: Lymphoscintigraphy Can Help. <i>Journal of Clinical Oncology</i> , 0, , . | 1.6 | 2 |
| 57 | Concerning pretreatment 18F-FDG PET/CT imaging in patients with large or locally advanced breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1801-1803. | 6.4 | 1 |
| 58 | Interim [18F]Fluorodeoxyglucoseâ€“Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2091-2092. | 1.6 | 1 |
| 59 | 18FDG-PET/CT Imaging in Breast Cancer Patients with Clinical Stage IIB or Higher. <i>Annals of Surgical Oncology</i> , 2020, 27, 1708-1709. | 1.5 | 1 |
| 60 | TEP/TDM au 18FDG dans le bilan initial et lâ€™Ã©valuation prÃ©coce de la chimiothÃ©rapie nÃ©oadjuvante du cancer du sein. <i>Medecine Nucleaire</i> , 2015, 39, 315-326. | 0.2 | 0 |
| 61 | Impact of molecular and histological subtype of breast cancer on 18FDG-PET/CT imaging: Knowledge gained from recent studies. <i>Medecine Nucleaire</i> , 2016, 40, 65-71. | 0.2 | 0 |
| 62 | FDG PET and FES PET Predict PFS on Endocrine Therapyâ€“Letter. <i>Clinical Cancer Research</i> , 2017, 23, 3474-3474. | 7.0 | 0 |
| 63 | Recommandations et rÃ©fÃ©rentiels. <i>Medecine Nucleaire</i> , 2019, 43, 1-4. | 0.2 | 0 |